Recent advances in microfluidic technologies enhance clinical utility of circulating tumor cells for cancer diagnostics, suggesting improved patient outcomes.
Circulating tumor cells (CTCs) are promising liquid-biopsy biomarkers for cancer diagnosis, treatment monitoring, metastasis assessment, and precision therapy. However, their clinical utility is constrained by extreme rarity, pronounced heterogeneity, and...
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: